Clinical Trial Update: Thymoglobulin (ATG) Dose Finding Study [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 dose-finding study of Thymoglobulin (ATG) for graft-versus-host disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Thymoglobulin (ATG) (anti-thymocyte globulin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Graft vs Host Disease | Phase 1, Phase 2 | Status: TERMINATED